The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Nanomedicine: Principles, Properties, and Regulatory Issues
Open accessAbstract
Several scientific areas have benefited significantly from the introduction of nanotechnology and the respective evolution. This is especially noteworthy in the development of new drug substances and products. This review focuses on the introduction of nanomedicines in the pharmaceutical market, and all the controversy associated to basic concepts related to these nanosystems, and the numerous methodologies applied for enhanced knowledge. Due to the properties conferred by the nanoscale, the challenges for nanotechnology implementation, specifically in the pharmaceutical development of new drug products and respective regulatory issues are critically discussed, mainly focused on the European Union context. Finally, issues pertaining to the current applications and future developments are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147
Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology
Oberdörster, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02187.x · Cited by 943
Techniques for physicochemical characterization of nanomaterials
Lin, P.-C., Lin, S., Wang, P. C., & Sridhar, R. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.006 · Cited by 708
Müller, R. H., Gohla, S., & Keck, C. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.007 · Cited by 702
Donaldson, K., Stone, V, Tran, C. L., Kreyling, W., & Borm, P. J. A. (2004) · Occupational and Environmental Medicine · doi:10.1136/oem.2004.013243 · Cited by 699
Protein corona formation around nanoparticles – from the past to the future
Pino, P. D., Pelaz, B., Zhang, Q., Maffre, P., Nienhaus, G. U., & Parak, W. J. (2014) · Mater. Horiz. · doi:10.1039/c3mh00106g · Cited by 555
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Nanotoxicology and in vitro studies: The need of the hour
Arora, S., Rajwade, J. M., & Paknikar, K. M. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.11.010 · Cited by 537
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Current in vitro methods in nanoparticle risk assessment: Limitations and challenges
Kroll, A., Pillukat, M. H., Hahn, D., & Schnekenburger, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.009 · Cited by 465
Comparative assessment of nanomaterial definitions and safety evaluation considerations
Boverhof, D. R., Bramante, C. M., Butala, J. H., Clancy, S. F., Lafranconi, M., West, J., & Gordon, S. C. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.06.001 · Cited by 443
Warheit, D. B. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfm279 · Cited by 419
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417
Choi, Y. H., & Han, H.-K. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 406
Photonic metamaterials by direct laser writing and silver chemical vapour deposition
Rill, M. S., Plet, C., Thiel, M., Staude, I., von Freymann, G., Linden, S., & Wegener, M. (2008) · Nature Materials · doi:10.1038/nmat2197 · Cited by 372
LOOMIS, D. P. (2006) · Occupational and Environmental Medicine · Cited by 331
Nanotherapeutics in the EU: an overview on current state and future directions
Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s55359 · Cited by 294
Nanomaterials in consumer products: a challenging analytical problem
Contado, C. (2015) · Frontiers in Chemistry · doi:10.3389/fchem.2015.00048 · Cited by 246
Biocompatibility and nanostructured materials: applications in nanomedicine
Adabi, M., Naghibzadeh, M., Adabi, M., Zarrinfard, M. A., Esnaashari, S. S., Seifalian, A. M., Faridi-Majidi, R., Tanimowo Aiyelabegan, H., & Ghanbari, H. (2017) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2016.1178134 · Cited by 244
Considerations on the EU definition of a nanomaterial: Science to support policy making
Bleeker, E. A. J., de Jong, W. H., Geertsma, R. E., Groenewold, M., Heugens, E. H. W., Koers-Jacquemijns, M., van de Meent, D., Popma, J. R., Rietveld, A. G., Wijnhoven, S. W. P., et al. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.11.007 · Cited by 229
High throughput toxicity screening and intracellular detection of nanomaterials
Collins, A. R., Annangi, B., Rubio, L., Marcos, R., Dorn, M., Merker, C., Estrela‐Lopis, I., Cimpan, M. R., Ibrahim, M., Cimpan, E., et al. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1413 · Cited by 207
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
Quality by design approach to understand the process of nanosuspension preparation
Verma, S., Lan, Y., Gokhale, R., & Burgess, D. J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.006 · Cited by 201
Winkler, D. A., Mombelli, E., Pietroiusti, A., Tran, L., Worth, A., Fadeel, B., & McCall, M. J. (2013) · Toxicology · doi:10.1016/j.tox.2012.11.005 · Cited by 184
Keck, C. M., & Müller, R. H. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.01.001 · Cited by 178
Characterization of nanomaterials for toxicity assessment
Sayes, C. M., & Warheit, D. B. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.58 · Cited by 177
In Silico Toxicology – Non-Testing Methods
Raunio, H. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00033 · Cited by 167
Agrahari, V., & Hiremath, P. S. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0039 · Cited by 164
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
Pearson, R. M., Juettner, V. V., & Hong, S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00108 · Cited by 158
(2011) · Biotechnology Law Report · doi:10.1089/blr.2011.9814 · Cited by 146
Costa, P. M., & Fadeel, B. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.014 · Cited by 142
Issues and concerns in nanotech product development and its commercialization
Kaur, I. P., Kakkar, V., Deol, P. K., Yadav, M., Singh, M., & Sharma, I. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.005 · Cited by 140
A critical appraisal of existing concepts for the grouping of nanomaterials
Arts, J. H. E., Hadi, M., Keene, A. M., Kreiling, R., Lyon, D. Y., Maier, M., Michel, K., Petry, T. W., Sauer, U. G., Warheit, D. B., et al. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.07.025 · Cited by 140
Nanomedicine: An unresolved regulatory issue
Chan, V. S. W. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.04.009 · Cited by 139
Quality-by-design of nanopharmaceuticals – a state of the art
Bastogne, T. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.05.014 · Cited by 134
Fadeel, B., Feliu, N., Vogt, C., Abdelmonem, A. M., & Parak, W. J. (2013) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1206 · Cited by 133
Arts, J. H. E., Irfan, M., Keene, A. M., Kreiling, R., Lyon, D. Y., Maier, M., Michel, K., Neubauer, N., Petry, T. W., Sauer, U. G., et al. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.11.020 · Cited by 133
Thomas, L., Roebben, G., Douglas, G., Calzolai, L., François, R., Gibson, P. N., & Christoph, K. (2012) · Joint Research Centre (European Commission) · doi:10.2787/63995 · Cited by 128
Revisiting the definition of biocompatibility.
Williams, D. F. (2003) · PubMed · Cited by 122
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century
Rusyn, I., & Daston, G. P. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1001925 · Cited by 110
Nanotoxicology: Advances and Pitfalls in Research Methodology
Azhdarzadeh, M., Saei, A. A., Sharifi, S., Hajipour, M. J., Alkilany, A. M., Sharifzadeh, M., Ramazani, F., Laurent, S., Mashaghi, A., & Mahmoudi, M. (2015) · Nanomedicine · doi:10.2217/nnm.15.130 · Cited by 102
Nanomedicines in the EU—Regulatory Overview
Pita, R., Ehmann, F., & Papaluca, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9967-1 · Cited by 101
At the Crossroads of Nanotoxicology in vitro : Past Achievements and Current Challenges
Hussain, S. M., Warheit, D. B., Ng, S. P., Comfort, K. K., Grabinski, C. M., & Braydich‐Stolle, L. K. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv106 · Cited by 95
Regulatory Challenges and Approaches to Characterize Nanomedicines and their Follow-On Similars
Mühlebach, S., Borchard, G., & Yildiz, S. (2015) · Nanomedicine · doi:10.2217/nnm.14.189 · Cited by 91
Equivalence of complex drug products: advances in and challenges for current regulatory frameworks
Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S. E., Borchard, G., Flühmann, B., Weinstein, V., Neervannan, S., Griffiths, E., Jiang, W., et al. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13347 · Cited by 90
Decision tree models to classify nanomaterials according to the DF4nanoGrouping scheme
Gajewicz, A., Puzyn, T., Odziomek, K., Urbaszek, P., Haase, A., Riebeling, C., Luch, A., Irfan, M. A., Landsiedel, R., van der Zande, M., et al. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1415388 · Cited by 85
Keeping it real: The importance of material characterization in nanotoxicology
Fadeel, B., Fornara, A., Toprak, M. S., & Bhattacharya, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.178 · Cited by 83
Rusyn, I., Sedykh, A., Low, Y., Guyton, K. Z., & Tropsha, A. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs095 · Cited by 81
Safety assessment of nanomaterials using an advanced decision-making framework, the DF4nanoGrouping
Landsiedel, R., Ma‐Hock, L., Wiench, K., Wohlleben, W., & Sauer, U. G. (2017) · Journal of Nanoparticle Research · doi:10.1007/s11051-017-3850-6 · Cited by 54
Juillerat‐Jeanneret, L., Dušinská, M., Fjellsbø, L. M., Collins, A. R., Handy, R. D., Riediker, M., & the NanoTEST Consortium (2013) · Nanotoxicology · doi:10.3109/17435390.2013.826743 · Cited by 51
Astier, A., Pai, A. B., Bissig, M., Crommelin, D. J. A., Flühmann, B., Hecq, J., Knoeff, J., Lipp, H., Baladrón, A. M., & Mühlebach, S. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13382 · Cited by 51
Nanosafety: towards safer design of nanomedicines
Fadeel, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12137 · Cited by 40
Bursten, J. R. S., Roco, M. C., Yang, W., Zhao, Y., Chen, C., Savolainen, K., Gerber, C., Kataoka, K., Krishnan, Y., Bayley, H., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.232 · Cited by 38
Nanotoxicology and nanomedicine: making development decisions in an evolving governance environment
Rycroft, T., Trump, B. D., Poinsatte‐Jones, K., & Linkov, I. (2018) · Journal of Nanoparticle Research · doi:10.1007/s11051-018-4160-3 · Cited by 37
Karakuş, C. Ö., Yue, C. X., & Wang, X. Z. (2015) · Procedia Engineering · doi:10.1016/j.proeng.2015.01.284 · Cited by 36
Regulatory Aspects of Oncologicals: Nanosystems Main Challenges
Gaspar, R. S., Florindo, H. F., Silva, L. C., Videira, M., Corvo, M. L., Martins, M. B. F., & Lima, B. S. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_15 · Cited by 36
Louro, H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72041-8_8 · Cited by 35
Keck, C. M., Jansch, M., & Müller, R. H. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics5010036 · Cited by 28
Cited by
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Abdel Maksoud, M. I. A., Fahim, R. A., Shalan, A. E., Abd Elkodous, M., Olojede, S. O., Osman, A. I., Farrell, C., Al-Muhtaseb, A. H., Awed, A. S., Ashour, A. H., et al. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-020-01075-w · Cited by 567
Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review
Viegas, C., Patrício, A. B., Prata, J. M., Nadhman, A., Chintamaneni, P. K., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061593 · Cited by 524
Metadata
- Authors
- Soares, S., Sousa, J., Pais, A., & Vitorino, C.
- Venue
- Frontiers in Chemistry
- Publisher
- Frontiers Media SA
- Published
- 2018-08-20
- Volume
- 6
- Pages
- 360-360
- ISSN
- 2296-2646 (ISSN-L)
- OpenAlex
- W2888712616
- Cited by
- 790
- References
- 68
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.